



Cancer Prevention and Control CIRB Meeting Agenda

September 25, 2025

I. Initial Review

NWU24-19-01, Evaluating the Feasibility of a Survivin Peptide Vaccine (SurVaxM) as an Interception Agent in Patients at High Risk for Lung Cancer (Version Date 08/05/25)

II. Initial ReReview

A232402CD, PAGODA: Randomized Trial of a Proactive Graduated Dose Modification Algorithm for FOLFOX Chemotherapy to Prevent Unplanned Delays (Version Date 08/25/25)

III. Continuing Review

A211901, Reaching Rural Cancer Survivors Who Smoke Using Text-Based Cessation Interventions (Version Date 03/21/25)

IV. Continuing Review

A222101, An Early Phase and Phase II Clinical Trial to Evaluate Ganglioside-Monosialic Acid (GM1) for Preventing Paclitaxel-Associated Neuropathy (Version Date 07/11/25)

V. Amendment Review

NWU20-04-01, Metformin for Chemoprevention of Lung Cancer in High-Risk Overweight or Obese Individuals (Version Date 08/21/25)

VI. Patient Recruitment Material Review

EAQ211, Social Genomic Mechanisms of Health Disparities among Adolescent and Young Adult (AYA) Cancer Survivors (Version Date 07/18/25)

VII. Amendment Review

UMI22-09-01, Phase IIA Trial of Acolbifene (20 mg) vs Low Dose Tamoxifen (5 mg) in Pre-menopausal Women at High Risk for Development of Breast Cancer (Version Date 09/04/25)

VIII. Continuing Review

NRG-CC014, Radiation Therapy for High-Risk Asymptomatic Bone Metastases: A Pragmatic Multicenter Randomized Phase 3 Clinical Trial (PREEMPT) (Version Date 02/28/25)

IX. Continuing Review

S1501, Prospective Observational Cohort Study of Patients with Metastatic Her-2+ Breast Cancer at Risk of Cardiac Toxicity (Version Date 02/11/25)

X. Continuing Review

S2408, A Randomized Phase III Blinded Trial of Lanreotide for the Prevention of Postoperative Pancreatic Fistula (Version Date 02/17/25)

XI. Continuing Review

URCC-18007, Randomized Placebo-Controlled Trial of Bupropion for Cancer-Related Fatigue (Version Date 02/25/25)
